Roivant Sciences Ltd
ROIV25.820USD
+4.680+22.14%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
17.81BValor de mercado
PerdaP/L TTM
Mais detalhes de Roivant Sciences Ltd Empresa
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Informações de Roivant Sciences Ltd
Código da empresaROIV
Nome da EmpresaRoivant Sciences Ltd
Data de listagemDec 03, 2020
CEOVenker (Eric)
Número de funcionários750
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço7Th Floor, 50 Broadway
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalSW1H 0DB
Telefone4412955950
Sitehttp://roivant.com/
Código da empresaROIV
Data de listagemDec 03, 2020
CEOVenker (Eric)
Executivos da empresa Roivant Sciences Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
41.26K
+761.00%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
37.59K
-148860.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-20494245.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Detalhamento da receita
FY2025Q1
Por EmpresaUSD
Nome
Receita
Proporção
VTAMA
55.13M
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
55.13M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
VTAMA
55.13M
0.00%
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
The Vanguard Group, Inc.
6.03%
Morgan Stanley Investment Management Inc. (US)
5.85%
Outro
57.83%
Investidores
Investidores
Proporção
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
The Vanguard Group, Inc.
6.03%
Morgan Stanley Investment Management Inc. (US)
5.85%
Outro
57.83%
Tipos de investidores
Investidores
Proporção
Investment Advisor
31.05%
Investment Advisor/Hedge Fund
20.09%
Hedge Fund
15.22%
Corporation
14.79%
Individual Investor
10.61%
Private Equity
9.04%
Research Firm
1.64%
Pension Fund
0.51%
Venture Capital
0.46%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
723
545.88M
78.49%
-26.29M
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Dexcel Pharma Technologies, Ltd.
102.85M
14.79%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
60.73M
8.73%
+5.24M
+9.44%
Sep 30, 2025
Ramaswamy (Vivek)
47.07M
6.77%
-1.00
-0.00%
Dec 15, 2025
The Vanguard Group, Inc.
38.72M
5.57%
-521.41K
-1.33%
Sep 30, 2025
Morgan Stanley Investment Management Inc. (US)
40.65M
5.85%
+7.28M
+21.82%
Sep 30, 2025
SB Investment Advisers (UK) Limited
40.32M
5.8%
-19.64M
-32.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
35.76M
5.14%
+233.57K
+0.66%
Sep 30, 2025
QVT Financial LP
28.08M
4.04%
-1.30M
-4.42%
Nov 19, 2025
Viking Global Investors LP
23.59M
3.39%
-10.64M
-31.09%
Sep 30, 2025
Rubric Capital Management LP
20.00M
2.88%
-370.34K
-1.82%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
Ver Mais
Invesco S&P MidCap 400 Pure Growth ETF
Proporção3.56%
Adaptiv Select ETF
Proporção2.91%
Virtus LifeSci Biotech Products ETF
Proporção2.79%
State Street SPDR S&P Biotech ETF
Proporção2.67%
WisdomTree US Value Fund
Proporção2.3%
ProShares Ultra Nasdaq Biotechnology
Proporção1.73%
Goldman Sachs Future Health Care Equity ETF
Proporção1.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.41%
Invesco Nasdaq Biotechnology ETF
Proporção1.33%
WisdomTree BioRevolution Fund
Proporção1.3%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
